These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
☒
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
SYMBID CORP.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Nevada
|
|
45-2859440
|
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(IRS
Employer Identification No.)
|
|
Marconistraat 16, 3029 AK Rotterdam, The Netherlands
|
|
|
|
(Address
of principal executive offices)
|
|
(Postal
Code)
|
|
+31(0)108900400
|
|
(Registrant’s
telephone number, including area code)
|
|
Large
Accelerated Filer ☐
|
|
Accelerated
Filer ☐
|
|
|
Non-Accelerated
Filer ☐
|
|
Smaller
reporting company ☒
|
|
|
(Do not
check if a smaller reporting company)
|
|||
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
1
|
|
|
PART I
|
|
2
|
|
ITEM
1.
|
BUSINESS
|
2
|
|
ITEM
1B.
|
UNRESOLVED STAFF COMMENTS
|
26
|
|
ITEM
2.
|
PROPERTIES
|
26
|
|
ITEM
3.
|
LEGAL PROCEEDINGS
|
26
|
|
ITEM
4.
|
MINE SAFETY DISCLOSURES
|
26
|
|
PART
II
|
|
26
|
|
ITEM
5.
|
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER
|
|
|
|
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
|
27
|
|
ITEM
6.
|
SELECTED FINANCIAL DATA
|
30
|
|
ITEM
7.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
|
30
|
|
ITEM
7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
41
|
|
ITEM
8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
41
|
|
ITEM
9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
|
41
|
|
ITEM
9A.
|
CONTROLS AND PROCEDURES
|
41
|
|
ITEM
9B.
|
OTHER INFORMATION
|
43
|
|
PART III
|
|
43
|
|
ITEM
10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
43
|
|
ITEM
11.
|
EXECUTIVE COMPENSATION
|
46
|
|
ITEM
12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
|
|
|
|
AND RELATED STOCKHOLDER MATTERS
|
47
|
|
ITEM
13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
48
|
|
ITEM
14.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
50
|
|
PART
IV
|
|
49
|
|
ITEM 15.
|
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
50
|
|
SIGNATURES
|
56
|
|
|
|
CREATE
: The entrepreneur and advisor together create a
funding request in a standardized deal format.
SHARE
: The standardized funding request can be shared with a
variety of institutional investors, and a network of over 36,000
private (crowdfunding) investors, who can invest from as little as
€ 20 ($22). Deals can be shared publically (open) or
privately (closed).
MATCH
: We match deals with the right investors based on
personalized preferences and can facilitate the settlement if
required.
MONITOR
: Ongoing financial analysis of private companies,
resulting in reporting for optimal risk and return management.
Financial data can be imported into our monitoring from the
accountant reporting system. Standardized data allows for comparing
the performance of companies. Investors and entrepreneurs both use
a personalized dashboard based on pre-set Key Performance
Indication (“KPI”) relating to a particular
company.
|
|
FAC
B.V.
|
On July
29, 2014, we entered into a Share Purchase Agreement with our
wholly owned subsidiary, Symbid Holding B.V., and FAC 2 B.V., a
limited liability corporation incorporated in The Netherlands.
Pursuant to the Share Purchase Agreement, we acquired FAC B.V.
(“Acquiree”), a limited liability corporation
incorporated in The Netherlands from FAC 2 B.V. in exchange for
2,750,000 shares of our restricted common stock. Acquiree owns a
perpetual, worldwide, exclusive license to infrastructure
technology upon which we intend to develop a platform to enable
cloud based financing solutions for SME’s, expanding on our
current equity based crowdfunding solutions in the Netherlands. The
license provides the required technology for ongoing monitoring of
private companies. Financial data can be imported into Symbid
monitoring from the accountant reporting system resulting in
powerful reporting for optimal risk and return management.
Standardized data allows for comparing the performance of
companies. Investors and entrepreneurs get a personal dashboard
with KPI’s for key variables and covenants.
|
|
Equidam
Holding B.V.
|
Equidam
Holding B.V., founded in August 2013, is one of the first companies
to be organized in any country as a crowdfunding service provider.
Started as an online valuation tool for private companies with a
particular focus on SMEs, Equidam Holding B.V. now also offers
monitoring services to investors on the Symbid platform. In
addition to Equidam Holding B.V.’s relationship with Symbid,
this company has entered partnerships with European crowdfunding
platforms to provide its services to these platforms as well.
Symbid owned a 7% direct interest in Equidam Holding B.V. following
an additional round of financing by Equidam Holding B.V. in which
we determined not to participate. In March 2017, this 7% interest
was sold for €15,000.
|
|
Kredietpaspoort
Coöperatie UA
|
The
Kredietpaspoort (Credit Passport) is an online
“passport” which provides up-to date information about
entrepreneurs and their business. The product is designed to be
used by private investors to quickly assess the prospects and
reliability of start-ups, SMEs and their owners before making an
investment. In essence, the Credit Passport is a simple-to-use yet
comprehensive online tool which provides the necessary information
for all lenders.
|
|
Period
|
High
|
Low
|
|
|
|
|
|
Quarter ended March
31, 2015
|
0.34
|
0.18
|
|
Quarter ended June
30, 2015
|
0.33
|
0.16
|
|
Quarter ended
September 30, 2015
|
0.30
|
0.15
|
|
Quarter ended
December 31, 2015
|
0.37
|
0.191
|
|
Quarter ended March
31, 2016
|
0.50
|
0.25
|
|
Quarter ended June
30, 2016
|
0.251
|
0.07
|
|
Quarter ended
September 30, 2016
|
0.15
|
0.04
|
|
Quarter ended
December 31, 2016
|
0.04
|
0.0082
|
|
Quarter ending
March 31, 2017*
|
0.015
|
0.011
|
|
* Through March 21,
2017
|
|
|
|
Plan
category
|
Number of
securities to be issued upon exercise of outstanding options,
warrants, units and rights
|
Weighted-average
exercise price of outstanding options, warrants, units and
rights
|
Number of
securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in
column)
|
|
|
|
|
|
|
Equity compensation
plans approved by security holders
(1)
|
0
|
N/A
|
3,724,432
|
|
Equity compensation
plans not approved by security holders
|
N/A
|
N/A
|
N/A
|
|
Total
|
0
|
N/A
|
0
|
|
|
Year
ended
December
31,
|
|
|
|
2016
|
2015
|
|
Revenues
|
|
|
|
Crowdfunding
|
$
195,632
|
$
282,155
|
|
The Funding
Network
|
22,399
|
47,975
|
|
Other
|
631
|
22,946
|
|
Total
revenues
|
218,662
|
353,076
|
|
Operating
expenses
|
|
|
|
Selling, general
and administrative
|
1,104,614
|
1,543,827
|
|
Professional
fees
|
376,720
|
721,963
|
|
Research and
development costs
|
32,869
|
59,930
|
|
Depreciation and
amortization
|
76,600
|
145,543
|
|
Bad debt expense
(recoveries)
|
(32,911
)
|
36,292
|
|
Impairment
expense
|
747,871
|
-
|
|
Total operating
expenses
|
2,305,763
|
2,507,555
|
|
|
|
|
|
Operating
loss
|
(2,087,101
)
|
(2,154,479
)
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
Interest expense
and amortization of debt discount
|
(294,599
)
|
(148,509
)
|
|
Gain on troubled
debt restructuring
|
1,169,253
|
-
|
|
Loss on cumulative
translation adjustment
|
(292,219
)
|
-
|
|
Other
income
|
-
|
11,504
|
|
Other
expense
|
(2,986
)
|
(7,791
)
|
|
Total other income
(expense)
|
579,449
|
(144,796
)
|
|
|
|
|
|
Net
loss
|
(1,507,652
)
|
(2,299,275
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
(17,029
)
|
(99,761
)
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(1,490,623
)
|
$
(2,199,514
)
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.03
)
|
$
(0.06
)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
Basic and
diluted
|
46,166,536
|
35,263,977
|
|
|
|
|
|
Share-based
compensation expense included in operating expenses:
|
|
|
|
Selling, general
and administrative
|
$
33,187
|
286,298
|
|
Professional
fees
|
-
|
152,711
|
|
Research and
development costs
|
(942
)
|
33,791
|
|
|
$
32,245
|
$
472,800
|
|
Name
|
|
Age
|
|
Position
|
|
Date Named to
Board of Directors
|
|
|
|
|
|
|
|
|
|
|
|
Korstiaan
Zandvliet
|
|
32
|
|
Director,
Chief Executive Officer and President
|
|
December
6, 2013
|
|
|
|
|
|
|
|
|
|
|
|
Maarten
van der Sanden
|
|
31
|
|
Chief
Executive Officer, Chief Operating Officer, Treasurer and
Secretary
|
|
N/A
|
|
|
Name &
Principal Position
|
|
Fiscal Year
ended
December
31,
|
Salary
($)
|
Bonus
($)
|
Stock Awards
($)
|
Option Awards
($)
|
Non-Equity
Incentive Plan Compensation
|
Non-Qualified
Deferred Compensation Earnings ($)
|
All Other
Compensation ($)
|
Total
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Korstiaan
Zandvliet, CEO
(1)(2)
|
|
2016
|
$
23,843
|
0
|
0
|
0
|
0
|
0
|
0
|
$
23,843
|
|
|
|
2015
|
$
60,396
|
0
|
31,303
(3)
|
0
|
0
|
0
|
0
|
$
91,699
|
|
Name and Address
of Beneficial Owner
|
Common
Stock
Beneficially
Owned
|
Percent of
Common Stock Beneficially Owned(1)
|
|
|
|
|
|
Korstiaan
Zandvliet
|
1,376,096
(2)
|
0.73
%
|
|
|
|
|
|
Maarten van der
Sanden
|
1,420,039
(3)
|
0.76
%
|
|
|
|
|
|
All directors and
executive officers as a group (2 persons)
|
2,796,135
|
1.49
%
|
|
|
|
|
|
CKR Law
LLP
1330 Avenue of the
Americas, 14th Floor
New York, NY
10019
|
140,515,750
(4)
|
75.01
%
|
|
Fee
Category
|
Year
ended
December 31,
2016
|
Year
ended
December 31,
2015
|
|
|
|
|
|
Audit
fees
(1)
|
$
69,600
|
$
75,000
|
|
Audit-related
fees
(2)
|
0
|
5,675
|
|
Tax
fees
(3)
|
0
|
0
|
|
All other
fees
(4)
|
0
|
0
|
|
Total
fees
|
$
69,600
|
$
80,675
|
|
Exhibit
Number
|
|
SEC Report
Reference Number
|
|
Description
|
|
|
|
|
|
|
|
2.1
|
|
2.1
|
|
Share
Exchange Agreement dated December 6, 2013, by and among Registrant,
Symbid Holding B.V. and the Shareholders of Symbid Holding
B.V (1)
|
|
3.1
|
|
3.1
|
|
Articles
of Incorporation of the Registrant (2)
|
|
3.2
|
|
3.1
|
|
Certificate
of Amendment to the Articles of Incorporation of the
Registrant (3)
|
|
3.3
|
|
3.2
|
|
By-Laws
of the Registrant (2)
|
|
3.4
|
|
3.4
|
|
Articles
of Association of Symbid Cooperatie U.A. (Unofficial English
Translation) (4)
|
|
3.5
|
|
3.5
|
|
Articles
of Association of Symbid Foundation. (Unofficial English
Translation) (4)
|
|
3.6
|
|
3.6
|
|
Articles
of Association of Symbid IP Foundation. (Unofficial English
Translation) (4)
|
|
4.1
|
|
4.1
|
|
Form of
Investor Warrant of the Registrant (1)
|
|
4.2
|
|
4.2
|
|
Form of
Broker Warrant of the Registrant (1)
|
|
4.3
|
|
4.1
|
|
Form of
2015 8% Convertible Promissory Note (9)
|
|
10.1
|
|
10.1
|
|
Split-Off
Agreement, dated as of December 6, 2013, by and among the
Registrant, Symbid Split Corp. and Holli
Morris (1)
|
|
10.2
|
|
10.2
|
|
General
Release Agreement, dated as of December 6, 2013, by and among the
Registrant, Symbid Split Corp. and Holli
Morris (1)
|
|
10.3
|
|
10.3
|
|
Form of
Lock-Up and No Short Selling Agreement between the Registrant and
the officers, directors and shareholders party
thereto (1)
|
|
10.4
|
|
10.4
|
|
Form of
Securities Purchase Agreement between the Registrant and the
investors party thereto (1)
|
|
10.5
|
|
10.5
|
|
Form of
Notice to Investors dated November 25, 2013 (1)
|
|
10.6
|
|
10.6
|
|
Placement
Agency Agreement, dated September 9, 2013, between the Registrant
and Gottbetter Capital Markets, LLC (1)
|
|
10.7
|
|
10.7
|
|
Placement
Agency Agreement, First Amendment, dated October 14, 2013, between
the Registrant and Gottbetter Capital Markets,
LLC (1)
|
|
10.8
|
|
10.8
|
|
Placement
Agency Agreement, Second Amendment, dated November 15, 2013,
between the Registrant and Gottbetter Capital Markets,
LLC (1)
|
|
10.9
|
|
10.9
|
|
Placement
Agency Agreement, Third Amendment, dated February 6, 2014, between
the Registrant and Gottbetter Capital Markets,
LLC (6)
|
|
10.10
|
|
10.10
|
|
Placement
Agency Agreement, Fourth Amendment, dated March 25, 2014, between
the Registrant and Gottbetter Capital Markets,
LLC (6)
|
|
10.11
|
|
10.11
|
|
Placement
Agency Agreement, Fifth Amendment, dated April 30, 2014, between
the Registrant and Gottbetter Capital Markets,
LLC (6)
|
|
10.12
|
|
10.12
|
|
Placement
Agency Agreement, Sixth Amendment, dated May 9, 2014, between the
Registrant and Gottbetter Capital Markets,
LLC (6)
|
|
10.13
|
|
10.9
|
|
Subscription
Escrow Agreement, dated as of September 9, 2013, among the
Registrant, CSC Trust Company of Delaware and Gottbetter Capital
Markets, LLC (1)
|
|
10.14
|
|
10.10
|
|
Subscription
Escrow Agreement, First Amendment dated as of November 15, 2013,
among the Registrant, CSC Trust Company of Delaware and Gottbetter
Capital Markets, LLC (1)
|
|
10.15
|
|
10.15
|
|
Subscription
Escrow Agreement, Second Amendment dated as of February 6, 2014,
among the Registrant, CSC Trust Company of Delaware and Gottbetter
Capital Markets, LLC (6)
|
|
10.16
|
|
10.16
|
|
Subscription
Escrow Agreement, Third Amendment dated as of March 25, 2014, among
the Registrant, CSC Trust Company of Delaware and Gottbetter
Capital Markets, LLC (6)
|
|
10.17
|
|
10.17
|
|
Subscription
Escrow Agreement, Fourth Amendment dated as of April 30, 2014,
among the Registrant, CSC Trust Company of Delaware and Gottbetter
Capital Markets, LLC (6)
|
|
10.18
|
|
10.18
|
|
Subscription
Escrow Agreement, Fifth Amendment dated as of May 9, 2014, among
the Registrant, CSC Trust Company of Delaware and Gottbetter
Capital Markets, LLC (6)
|
|
10.19
|
|
10.11
|
|
Escrow
Agreement dated as of December 6, 2013 by and among the Registrant,
the Indemnification and Shareholder Representative named therein
and Gottbetter & Partners, LLP (1)
|
|
10.20
|
|
10.12
|
|
Employment
Services Agreement, dated December 6, 2013, between the Registrant
and Korstiaan Zandvliet (1)
|
|
10.21
|
|
10.13
|
|
Employment
Services Agreement, dated December 6, 2013, between the Registrant
and Robin Slakhorst (1)
|
|
10.22
|
|
10.14
|
|
Employment
Services Agreement, dated December 6, 2013, between the Registrant
and Maarten van der Sanden (1)
|
|
10.23
|
|
10.1
|
|
Employment
Services Agreement, dated April 15, 2014 between the Registrant and
Philip Cooke (5)
|
|
10.24
|
|
10.15
|
|
Registrant’s
2013 Equity Incentive Plan (1)
|
|
10.25
|
|
10.16
|
|
Form of
Registration Rights Agreement (1)
|
|
10.26
|
|
10.17
|
|
License
Agreement dated April 13, 2011 by and between Symbid B.V. and
Symbid Cooperatie U.A. (1)
|
|
10.27
|
|
10.18
|
|
Platform
Management Services Agreement April 6, 2011 by and between Symbid
B.V. and Symbid Cooperatie U.A. (1)
|
|
10.28
|
|
10.19
|
|
Intellectual
Property Transfer Agreement dated October 16, 2013 by and between
Symbid B.V. and Stichting Symbid IP
Foundation (1)
|
|
10.29
|
|
10.20
|
|
Intellectual
Property License and Transfer Agreement dated October 16, 2013 by
and between Stichting Symbid IP Foundation and Symbid Holding
B.V. (1)
|
|
10.30
|
|
10.21
|
|
Addendum
1 dated December 5, 2013 to Intellectual Property License and
Transfer Agreement dated October 16, 2013 by and between Stichting
Symbid IP Foundation and Symbid Holding B.V. (1)
|
|
10.31
|
|
10.22
|
|
Intellectual
Property Sublicense and Transfer Agreement dated December 5, 2013
by and between Symbid Holding B.V. and Symbid
B.V. (1)
|
|
10.32
|
|
10.1
|
|
Share
Purchase Agreement dated July 29, 2014, between the Registrant,
Symbid Holding B.V., and FAC 2 B.V (7)
|
|
10.33
|
|
10.25
|
|
Agreement
dated December 8, 2014 by and between the Registrant and Fortion
Holding B.V. (8)
|
|
10.34
|
|
10.26
|
|
Subscription
and shareholder agreement dated December, 2014, between the
Registrant, Banca Sella Holding SPA and Marco Bicocchi
Pichi (8)
|
|
10.35
|
|
10.1
|
|
Employment
Services Agreement dated as of November 1, 2015 between Registrant
and Dick Kooij (10)
|
|
10.36
|
|
10.2
|
|
Amendment
No. 1 dated as of November 16, 2015 to Employment Services
Agreement between Registrant and Dick Kooij (10)
|
|
10.37
|
|
10.1
|
|
Financial
Public Relations Agreement dated as of July 1, 2015 between
Registrant and Dynasty Wealth LLC (11)
|
|
10.38
|
|
10.1
|
|
First
Amendment dated as of November 11, 2015 to Financial Public
Relations Agreement dated as of July 1, 2015 between Registrant and
Dynasty Wealth LLC (9)
|
|
10.39
|
|
10.2
|
|
Form of
Restricted Stock Unit Agreement of
Registrant (12)
|
|
10.40
|
|
10.1
|
|
Resignation
Letter of Hendrik Kasteel dated April 5, 2016 (13)
|
|
10.41
|
|
10.2
|
|
Resignation
Letter of Vincent Lui dated April 5, 2016 (13)
|
|
10.42
|
|
10.3
|
|
Resignation
Letter of Jerome Koelewijn dated April 5, 2016 (13)
|
|
10.43
|
|
10.1
|
|
Form of
November 15, 2016 Note Termination and Conversion Agreement (2016
Notes) (14)
|
|
10.44
|
|
10.2
|
|
Form of
November 15, 2016 Note Termination and Conversion Agreement (2015
Notes) (14)
|
|
10.45
|
|
10.3
|
|
Right
of First Refusal Agreement dated November 15,
2016 (14)
|
|
10.46
|
|
10.4
|
|
Intellectual
Property License Termination Agreement dated November 15, 2016
between Symbid B.V. and Symbid Coöperatie U.A.
(14)
|
|
10.47
|
|
10.5
|
|
Addendum
2 dated November 15, 2016 to October 16, 2013 Intellectual Property
License and Transfer Agreement between Stichting Symbid IP
Foundation and Symbid Holding B.V. (14)
|
|
10.48
|
|
10.6
|
|
Intellectual
Property License and Transfer Agreement dated November 15, 2016
between Symbid Coöperatie U.A. and Stichting Symbid IP
Foundation (14)
|
|
10.49
|
|
10.7
|
|
Securities
Purchase Agreement dated as of December 9,2016 between Registrant
and CKR Law LLP (14)
|
|
14.1
|
|
14.1
|
|
Code of
Ethics (2)
|
|
21.1*
|
|
|
|
Subsidiaries
of Registrant
|
|
23.1*
|
|
|
|
Consent
of Independent Registered Public Accounting Firm
|
|
31.1*
|
|
|
|
Certification
of Principal Executive Officer pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002**
|
|
31.2*
|
|
|
|
Certification
of Principal Financial Officer pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002**
|
|
32.1*
|
|
|
|
Certifications
of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002**
|
|
32.2*
|
|
|
|
Certifications
of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002**
|
|
101.INS*
|
|
|
|
XBRL
Instance Document***
|
|
101.SCH*
|
|
|
|
XBRL
Taxonomy Extension Schema Document***
|
|
101.CAL*
|
|
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document***
|
|
101.DEF*
|
|
|
|
XBRL
Taxonomy Extension Definition Linkbase Document***
|
|
101.LAB*
|
|
|
|
XBRL
Taxonomy Extension Label Linkbase Document***
|
|
|
Symbid Corp.
|
|
|
|
|
|
|
|
|
Dated: March 31,
2017
|
By:
|
/s/
Korstiaan Zandvliet
|
|
|
|
|
Korstiaan
Zandvliet
|
|
|
|
|
Chief Executive
Officer and President
|
|
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
|
|
| Dated: March 31, 2017 |
By:
|
/s/
Maarten van der Sanden
|
|
|
|
|
Maarten van der
Sanden
|
|
|
|
|
Chief Financial Officer, Treasurer and Secretary |
|
|
|
|
(Principal Financial Officer) |
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Korstiaan Zandvliet
|
|
Chief
Executive Officer and President (Principal
|
|
March
31, 2017
|
|
Korstiaan
Zandvliet
|
|
Executive
Officer) and Director
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
Report
of Independent Registered Public Accounting Firm
|
F-1
|
|
|
|
|
Consolidated
Balance Sheets as of December 31, 2016 and 2015
|
F-2
|
|
|
|
|
Consolidated
Statements of Operations for the Years Ended December 31, 2016 and
2015
|
F-3
|
|
|
|
|
Consolidated
Statements of Comprehensive Loss for the Years Ended December 31,
2016 and 2015
|
F-4
|
|
|
|
|
Consolidated
Statements of Stockholders’ Equity (Deficit) for the years
ended December 31, 2016 and 2015
|
F-5
|
|
|
|
|
Consolidated
Statements of Cash Flows for the Years Ended December 31, 2016 and
2015
|
F-6
|
|
|
|
|
Notes
to Consolidated Financial Statements
|
F-7
|
|
|
December
31,
|
December
31,
|
|
|
2016
|
2015
|
|
ASSETS
|
|
|
|
Current
assets
|
|
|
|
Cash
|
$
9,677
|
$
553,696
|
|
Accounts
receivable, less allowance for doubtful accounts of $-0- and
$39,847 respectively
|
-
|
64,639
|
|
Prepaid expenses
and other current assets
|
32,544
|
42,553
|
|
Total current
assets
|
42,221
|
660,888
|
|
|
|
|
|
Property and
equipment, at cost, less accumulated depreciation
|
-
|
15,108
|
|
Investments in
associated companies
|
1,095
|
1,134
|
|
Intangible assets,
net
|
-
|
785,070
|
|
Total
assets
|
$
43,316
|
$
1,462,200
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' (DEFICIENCY) EQUITY
|
|
|
|
Current
liabilities
|
|
|
|
Accounts
payable
|
$
16,515
|
$
88,774
|
|
Accrued expenses
and other current liabilities
|
37,077
|
301,896
|
|
Current maturities
of notes payable
|
-
|
32,993
|
|
Subordinated loan
– related party
|
-
|
73,016
|
|
Total current
liabilities
|
53,592
|
496,679
|
|
|
|
|
|
Notes payable, less
current maturities
|
-
|
49,476
|
|
8% Convertible
promissory notes payable, net of $-0- and $722,622 discount,
respectively
|
-
|
587,378
|
|
Total
liabilities
|
53,592
|
1,133,533
|
|
|
|
|
|
Commitments
|
|
|
|
|
|
|
|
Stockholders'
(Deficiency) Equity
|
|
|
|
|
|
|
|
Preferred
stock
|
|
|
|
Authorized:
$0.001 par value, 10,000,000 shares authorized
|
-
|
-
|
|
Issued
and outstanding: nil preferred shares
|
|
|
|
Common
stock
|
|
|
|
Authorized:
$0.001 par value, 290,000,000 shares authorized
|
|
|
|
Issued
and outstanding: 187,329,355 and 36,909,472,
respectively
|
187,329
|
36,909
|
|
|
|
|
|
Additional paid-in
capital
|
8,287,292
|
7,635,104
|
|
Accumulated other
comprehensive loss
|
-
|
(322,183
)
|
|
Accumulated
deficit
|
(8,484,897
)
|
(6,994,274
)
|
|
Total Symbid Corp.
stockholders' (deficiency) equity
|
(10,276
)
|
355,556
|
|
Noncontrolling
interests
|
-
|
(26,889
)
|
|
Total stockholders'
(deficiency) equity
|
(10,276
)
|
328,667
|
|
Total liabilities
and stockholders' equity
|
$
43,316
|
$
1,462,200
|
|
|
Year
ended
December
31,
|
|
|
|
2016
|
2015
|
|
Revenues
|
|
|
|
Crowdfunding
|
$
195,632
|
$
282,155
|
|
The Funding
Network
|
22,399
|
47,975
|
|
Other
|
631
|
22,946
|
|
Total
revenues
|
218,662
|
353,076
|
|
Operating
expenses
|
|
|
|
Selling, general
and administrative
|
1,104,614
|
1,543,827
|
|
Professional
fees
|
376,720
|
721,963
|
|
Research and
development costs
|
32,869
|
59,930
|
|
Depreciation and
amortization
|
76,600
|
145,543
|
|
Bad debt expense
(recoveries)
|
(32,911
)
|
36,292
|
|
Impairment
expense
|
747,870
|
-
|
|
Total operating
expenses
|
2,305,763
|
2,507,555
|
|
|
|
|
|
Operating
loss
|
(2,087,101
)
|
(2,154,479
)
|
|
|
|
|
|
Other
income (expense)
|
|
|
|
Interest expense
and amortization of debt discount
|
(294,599
)
|
(148,509
)
|
|
Gain on troubled
debt restructuring
|
1,169,253
|
-
|
|
Loss on cumulative
translation adjustment
|
(292,219
)
|
-
|
|
Other
income
|
-
|
11,504
|
|
Other
expense
|
(2,986
)
|
(7,791
)
|
|
Total other income
(expense)
|
579,449
|
(144,796
)
|
|
|
|
|
|
Net
loss
|
(1,507,652
)
|
(2,299,275
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
(17,029
)
|
(99,761
)
|
|
|
|
|
|
Net
loss attributable to Symbid Corp. stockholders
|
$
(1,490,623
)
|
$
(2,199,514
)
|
|
|
|
|
|
Basic and diluted
net loss per common share
|
$
(0.03
)
|
$
(0.06
)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
Basic and
diluted
|
46,166,536
|
35,263,977
|
|
|
|
|
|
Share-based
compensation expense included in operating expenses:
|
|
|
|
Selling, general
and administrative
|
$
33,187
|
286,298
|
|
Professional
fees
|
-
|
152,711
|
|
Research and
development costs
|
(942
)
|
33,791
|
|
|
$
32,245
|
$
472,800
|
|
|
Year
ended
December
31,
|
|
|
|
2016
|
2015
|
|
|
|
|
|
Net
loss
|
$
(1,507,652
)
|
$
(2,299,275
)
|
|
Other comprehensive
loss:
|
|
|
|
Foreign currency
translation income (loss)
|
322,183
|
(143,661
)
|
|
Comprehensive
loss
|
(1,185,469
)
|
(2,442,936
)
|
|
|
|
|
|
Net loss
attributable to noncontrolling interests
|
(17,029
)
|
(99,761
)
|
|
Foreign currency
translation income (loss) attributable to noncontrolling
interests
|
(827
)
|
10,129
|
|
Comprehensive loss
attributable to noncontrolling interests
|
(17,856
)
|
(89,632
)
|
|
|
|
|
|
Comprehensive loss
attributable to Symbid Corp. stockholders
|
$
(1,167,613
)
|
$
(2,353,304
)
|
|
|
Symbid
Corp. Stockholders’
|
|
|
|||||
|
|
Number
of
Shares
|
Common
Stock
|
Additional
Paid-In
Capital
|
Accumulated
Other
Comprehensive
Loss
|
Accumulated
Deficit
|
Total Symbid
Corp.
Stockholders'
Equity
|
Noncontrolling
Interests
|
Total
Stockholders'
Equity
|
|
Balance,
January 1, 2015
|
33,182,100
|
$
33,182
|
$
5,367,771
|
$
(178,522
)
|
$
(4,794,760
)
|
$
427,671
|
$
(78,025
)
|
$
349,646
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from the
issuance of common stock, net of issuance costs
|
1,448,232
|
1,448
|
722,668
|
-
|
-
|
724,116
|
-
|
724,116
|
|
Issuance of common
stock for services
|
530,904
|
531
|
181,856
|
-
|
-
|
182,387
|
-
|
182,387
|
|
Reclassification of
warrants
|
-
|
-
|
160,945
|
-
|
-
|
160,945
|
-
|
160,945
|
|
Share Based
compensation related to employee share based awards
|
988,236
|
988
|
320,166
|
-
|
-
|
321,154
|
-
|
321,154
|
|
Symbid Italia
formation
|
-
|
-
|
(129,918
)
|
-
|
-
|
(129,918
)
|
140,768
|
10,850
|
|
Conversion of 8%
Notes
|
760,000
|
760
|
189,240
|
-
|
-
|
190,000
|
-
|
190,000
|
|
Beneficial
conversion feature
|
-
|
-
|
822,376
|
-
|
-
|
822,376
|
-
|
822,376
|
|
Translation
adjustment
|
-
|
-
|
-
|
(143,661
)
|
-
|
(143,661
)
|
10,129
|
(133,532
)
|
|
Net
loss
|
-
|
-
|
-
|
-
|
(2,199,514
)
|
(2,199,514
)
|
(99,761
)
|
(2,299,275
)
|
|
Balance,
December 31, 2015
|
36,909,472
|
$
36,909
|
$
7,635,104
|
$
(322,183
)
|
$
(6,994,274
)
|
$
355,556
|
$
(26,889
)
|
$
328,667
|
|
Derecognition of
Symbid Italia
|
-
|
-
|
-
|
-
|
-
|
-
|
(46,171
)
|
(46,171
)
|
|
Derecognition of
Symbid Coop
|
-
|
-
|
-
|
|
-
|
-
|
90,916
|
90,916
|
|
Issuance of common
stock under SPA Agreement
|
149,863,484
|
149,863
|
(25,793
)
|
|
-
|
124,070
|
-
|
124,070
|
|
Issuance of common
stock for services
|
249,567
|
250
|
77,451
|
|
-
|
77,701
|
|
77,701
|
|
Share based
compensation
|
306,832
|
307
|
50,530
|
|
-
|
50,837
|
|
50,837
|
|
Beneficial
conversion feature
|
-
|
-
|
550,000
|
|
-
|
550,000
|
|
550,000
|
|
Translation
adjustment
|
-
|
-
|
|
322,183
|
-
|
322,183
|
(827
)
|
321,356
|
|
Net
loss
|
-
|
-
|
|
|
(1,490,623
)
|
(1,490,623
)
|
(17,029
)
|
(1,507,652
)
|
|
Balance,
December 31, 2016
|
187,329,355
|
$
187,329
|
$
8,287,292
|
$
0
|
$
(8,484,897
)
|
$
(10,276
)
|
$
0
|
$
(10,276
)
|
|
|
Year ended
December 31,
|
|
|
|
2016
|
2015
|
|
Cash
flows from operating activities
|
|
|
|
Net
loss
|
$
(1,507,652
)
|
$
(2,299,275
)
|
|
Adjustments to
reconcile net loss to net cash
|
|
|
|
used in operating
activities
|
|
|
|
Employee and
non-employee share based compensation
|
32,245
|
320,089
|
|
Shares issued under
service agreements
|
-
|
182,387
|
|
Depreciation and
amortization
|
76,600
|
145,543
|
|
Amortization of
debt discount
|
174,091
|
99,753
|
|
Impairment of
intangible asset
|
747,870
|
-
|
|
Gain on troubled
debt restructuring
|
(1,169,253
)
|
-
|
|
Loss on foreign
currency translation
|
292,219
|
-
|
|
Warrant liability -
fair value adjustment
|
-
|
7,791
|
|
Bad debt
recoveries
|
(10,371
)
|
36,292
|
|
Loss on liquidation
of Symbid Italia
|
2,986
|
-
|
|
Gain on sale of
investment in Gambitious B.V.
|
-
|
(11,504
)
|
|
Changes
in assets and liabilities
|
|
|
|
Accounts
receivable
|
64,639
|
(60,926
)
|
|
Prepaid expenses
and other current assets
|
10,009
|
5,431
|
|
Accounts
payable
|
(72,259
)
|
(262,073
)
|
|
Accrued expenses
and other current liabilities
|
264,819
|
33,449
|
|
Net cash used in
operating activities
|
(1,094,057
)
|
(1,803,043
)
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
Proceeds from sale
of associated companies
|
$
-
|
$
20,309
|
|
Net payment from
liquidation of Symbid Italia
|
(44,744
)
|
-
|
|
Acquisition of
property and equipment
|
(5,784
)
|
(9,885
)
|
|
Net cash (used in)
provided by investing activities
|
(50,528
)
|
10,424
|
|
|
|
|
|
Cash
flows from financing activities
|
|
|
|
Line of credit,
net
|
$
67,420
|
$
-
|
|
Repayments of notes
payable
|
(16,740
)
|
(33,583
)
|
|
Proceeds from
convertible notes
|
550,000
|
1,500,000
|
|
Proceeds from the
issuance of common stock, net of issuance costs
|
-
|
724,116
|
|
Net cash provided
by financing activities
|
600,680
|
2,190,533
|
|
|
|
|
|
Effect of exchange
rate changes on cash
|
(114
)
|
(77,286
)
|
|
Net
(decrease) / increase in cash
|
(544,019
)
|
320,628
|
|
|
|
|
|
Cash and cash
equivalents, beginning of period
|
553,696
|
233,068
|
|
Cash
and cash equivalents, end of period
|
$
9,677
|
$
553,696
|
|
|
|
|
|
Supplemental
cash flow disclosures
|
|
|
|
Interest
paid
|
$
4,511
|
$
13,609
|
|
|
|
|
|
Non-cash
investing and financing activities
|
|
|
|
Change in accrued
expenses related to non-employee share based payments
|
$
98,242
|
$
1,065
|
|
Change in accrued
expenses related to shares issued under SPA agreement
|
124,070
|
|
|
Deconsolidation of
Symbid Italia assets
|
5,901
|
-
|
|
Deconsolidation of
Coop assets
|
90,945
|
-
|
|
Transfer of
Rabobank debt facility and fixed assets to Symbid Coop
|
122,292
|
-
|
|
Beneficial
conversion feature
|
550,000
|
-
|
|
Conversion of 8%
convertible promissory notes
|
-
|
190,000
|
|
Reallocation of
noncontrolling interests
|
-
|
129,918
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Current
assets
|
$
-
|
$
73,600
|
|
Current
liabilities
|
$
-
|
$
186,214
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
VAT return Q4 2016/
2015
|
$
-
|
$
17,827
|
|
Revenues to be
invoiced
|
1,370
|
2,472
|
|
Wage tax
refund
|
3,602
|
-
|
|
Other prepaid
expenses
|
6,996
|
10,883
|
|
Insurance
premiums
|
13,484
|
11,371
|
|
Intercompany
balance Symbid Coöperatie UA and
Symbid Crowdfunding
B.V.
|
7,092
|
-
|
|
|
$
32,544
|
$
42,553
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Computers and
equipment
|
$
10,057
|
$
20,868
|
|
Less - Accumulated
depreciation
|
(1,765
)
|
(5,760
)
|
|
Impairment
|
(7,807
)
|
-
|
|
Translation
adjustment
|
(485
)
|
-
|
|
|
$
-
|
$
15,108
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Software
|
$
1,019,103
|
$
984,267
|
|
Less - Accumulated
amortization
|
(274,394
)
|
(199,197
)
|
|
Impairment
|
(740,063
)
|
-
|
|
Translation
adjustment
|
(4,646
)
|
-
|
|
|
$
-
|
$
785,070
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Advisory
costs
|
$
3,786
|
$
89,829
|
|
Interest
|
-
|
45,863
|
|
Wage tax
return
|
-
|
19,035
|
|
Holiday pay
allowance/Net salary
|
8,647
|
24,533
|
|
Penalty
waiver
|
14,630
|
14,630
|
|
Marketing
|
-
|
38,069
|
|
Accrued stock
liability
|
-
|
20,541
|
|
VAT return Q4 2016/
2015
|
7,028
|
-
|
|
Other current
liabilities
|
2,986
|
49,396
|
|
|
$
37,077
|
$
301,896
|
|
|
Year
ended
December 31,
2016
|
|
2015 and 2016 Notes
payable
|
$
761,467
*
|
|
Accrued interest on
2015 and 2016 Notes payable
|
145,068
*
|
|
Subordinated loan
– related party
|
71,993
*
|
|
Accrued interest-
Subordinated loan – related party
|
14,942
*
|
|
Settlement of
Symbid Coop payable
|
24,974
**
|
|
Settlement of
accounts payable – creditors
|
150,809
***
|
|
|
$
1,169,253
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Line of
credit
|
$
-
|
$
-
|
|
Working capital
facility
|
-
|
82,469
|
|
Subordinated loan
– related party
|
-
|
73,016
|
|
8% Convertible
promissory notes
|
-
|
587,378
|
|
Total notes
payable
|
-
|
742,863
|
|
Less - Current
Maturities
|
-
|
(106,009
)
|
|
Notes
payable, less current maturities
|
$
-
|
$
636,854
|
|
|
Principal
|
Accrued
Interest
|
Unamortized
Debt
Discount
|
Balance as of
December
31,
2015
|
|
8% Convertible
promissory notes July 14, 2015
|
$
60,000
|
$
2,213
|
$
(12,964
)
|
$
49,249
|
|
8% Convertible
promissory notes September 8, 2015
|
1,250,000
|
31,111
|
(709,658
)
|
571,453
|
|
|
$
1,310,000
|
$
33,324
|
$
(722,622
)
|
$
620,702
|
|
|
Principal
|
Accrued
Interest
|
Unamortized
Debt
Discount
|
Balance as of
December
31,
2016
|
|
8% Convertible
promissory notes July 14, 2015
|
$
0
|
$
0
|
$
0
|
$
0
|
|
8% Convertible
promissory notes September 8, 2015
|
0
|
0
|
0
|
0
|
|
8% Convertible
promissory notes June 1, 2016
|
0
|
0
|
0
|
0
|
|
|
$
0
|
$
0
|
$
0
|
$
0
|
|
|
Year ended
December 31,
|
|
|
|
2016
|
2015
|
|
Cash Interest
Expense
|
|
|
|
Coupon
interest expense
|
$
118,918
|
$
48,756
|
|
Noncash Interest
Expense
|
|
|
|
Amortization
of debt discount
|
175,681
|
99,753
|
|
|
$
294,599
|
$
148,509
|
|
|
Year Ended
December 31,
|
|
|
|
2016
|
2015
|
|
Symbid Coop-
100%
|
$
(23,116
)
|
$
43,202
|
|
Symbid Italia
– 49.9%
|
40,145
|
56,559
|
|
Total
net loss attributable to NCI
|
$
17,029
|
$
99,761
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
Symbid Coop-
100%
|
$
-
|
$
(112,614
)
|
|
Symbid Italia
– 49.9%
|
-
|
85,725
|
|
Total
equity (deficiency) attributable to noncontrolling
interests
|
$
-
|
$
(26,889
)
|
|
|
December
31,
|
|
|
|
2016
|
2015
|
|
|
|
|
|
U.S. Statutory
rates
|
34
%
|
34
%
|
|
Foreign income not
recognized in the U.S.
|
(34
%)
|
(34
%)
|
|
Dutch income tax
rate
|
20
%
|
20
%
|
|
Equity Method
Pick-Up – Symbid Holding
|
(5.80
)
|
(9.02
)
|
|
Other, less than
1%
|
(0.05
)
|
(0.10
)
|
|
Effective income
tax rate
|
14.15
|
10.88
|
|
Effect on valuation
allowance
|
(14.15
)
|
(10.88
)
|
|
Effective income
tax rate
|
0
%
|
0
%
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|